A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Completed · Phase 2/Phase 3

Conditions studied: Hereditary Angioedema, HAE, Prophylaxis

In brief

This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).

Key facts

Study ID
NCT03472040
Run by
BioCryst Pharmaceuticals
People needed
387
Starts
2018-02-16
Expected to finish
2022-04-27
Last updated by the study team
2023-06-18

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.